Seborrheic Dermatitis
Clinical Snapshot
Seborrheic dermatitis is a chronic, relapsing inflammatory skin condition driven by an individual's inflammatory response to Malassezia yeast — a fungus that lives normally on everyone's skin — rather than by a true infection or an external contact trigger.[1][2] It affects the sebum-rich ("seborrheic") areas of the body: the scalp, the face (especially the eyebrows, glabella, nasolabial folds, and ears), the central chest, and body folds.[2] Dandruff is simply the mild, non-inflammatory end of this same spectrum — fine scalp scaling without significant redness — while seborrheic dermatitis proper adds visible erythema and thicker, greasy, yellow-white scale.[3][1] An important, distinct presentation of the same underlying process occurs in infants as cradle cap — see Special Populations.
Overall prevalence is reported at roughly 1-5% of the general population, and age follows a genuinely bimodal pattern: a peak in infancy (2-12 months, as cradle cap) and a second peak in adolescence and early adulthood, when sebaceous gland activity rises.[1][4] The condition is more common, and tends to run more severe, in men, an observation consistently attributed to androgen-driven sebaceous gland activity.[1][3][4] Two associations are clinically important enough to actively screen for. Seborrheic dermatitis is markedly more common in HIV-positive patients — roughly 30-83%, compared with 3-5% in the general population — and often serves as one of the earliest cutaneous markers of HIV infection, sometimes preceding the diagnosis itself.[4] It is also significantly more prevalent in Parkinson's disease: a recent cross-sectional study found it in roughly two-thirds of patients with Parkinson's disease, compared with about 1 in 10 controls, with severity tracking Parkinson's motor-symptom severity.[5] See Etiology and Risk Factors and Special Populations for the full detail on both. Flares are also reliably provoked by cold, dry weather and by emotional stress.[1][4][3]
Recognize the Condition
Pathophysiology — why this looks the way it does
The pathophysiology has three interacting pieces: overgrowth of Malassezia species (principally M. furfur, M. globosa, and M. restricta) on sebum-rich skin; the yeast's lipase activity, which breaks down sebum triglycerides into free fatty acids that directly irritate the epidermis and trigger inflammation; and an individual, genetically-influenced inflammatory and immune response to that irritation, which is what actually determines whether a given amount of yeast produces visible disease in a given patient.[1][2] Skin-surface lipid quantity and composition also differ measurably between affected patients and unaffected controls, supporting a real sebum/hormonal contribution alongside the yeast itself.[4] This is a genuinely different mechanism from irritant or allergic contact dermatitis, which are trigger-driven direct skin-barrier injuries or Type IV hypersensitivity reactions to an external substance the skin has directly touched. Seborrheic dermatitis is not a contact reaction, has no identifiable external trigger to avoid, and is not caused by, or a form of, either type of contact dermatitis — this is exactly why it is covered as its own chapter, separate from this platform's Contact Dermatitis chapter, rather than as a subtype within it.
Distribution — sebum-rich sites
Where it shows up, and how it looks
Scalp
The most common site, and the one where the disease spectrum is easiest to see end to end: fine, dry or greasy white flaking without significant redness (dandruff, the mild, non-inflammatory end of the spectrum) grades into frank seborrheic dermatitis — erythematous patches with thicker, greasy, yellow-white scale, sometimes with mild itching.[3][1]
Face
The eyebrows, glabella (between the brows), nasolabial folds, and the skin behind and within the ears are the classic facial sites, along with the eyelid margins (blepharitis).[1][2] Erythema and greasy scale concentrated in these specific sites, rather than a diffuse facial rash, is a genuinely useful pattern-recognition clue.
Chest, body folds, and other sites
The central anterior chest, upper back, axillae, and groin can all be involved, following the same sebum-rich, fold-prone distribution as the scalp and face.[2]
Darker skin tones
Seborrheic dermatitis in richly pigmented skin more often presents as petaloid seborrheic dermatitis — annular (ring-shaped), petal-like patches, sometimes with pronounced hypo- or hyperpigmentation that can persist well after the inflammation itself has cleared — rather than the straightforward erythema seen in lighter skin.[3][2] Counsel proactively that this pigment change is an expected part of the disease course, not a sign of treatment failure or a different diagnosis (see Patient Education within Monitoring and Follow-Up).
Risk Factors
- Male sex — androgen-driven sebaceous gland activity is the leading explanation for both the higher prevalence and the greater severity seen in men.[1][3][4]
- Age: the bimodal peaks of infancy (2-12 months, presenting as cradle cap) and adolescence/early adulthood, both periods of relatively higher sebaceous gland activity.[1]
- HIV infection/immunosuppression — prevalence rises to roughly 30-83% in HIV-positive patients, compared with 3-5% in the general population, and seborrheic dermatitis often appears early in the course of HIV disease, sometimes as one of its first cutaneous signs; in some settings its appearance has been used as a practical predictor of underlying HIV infection.[4] See Diagnosis/Differential and Red Flags/Refer for when to consider HIV testing.
- Parkinson's disease — a recent cross-sectional study found seborrheic dermatitis in 66.6% of patients with akinetic-rigid Parkinson's disease and 69.7% of patients with tremor-predominant Parkinson's disease, compared with 10% of essential-tremor controls, with the akinetic-rigid group also showing significantly greater seborrheic dermatitis severity — plausibly reflecting shared cutaneous autonomic dysfunction.[5]
- Other neurologic conditions, including a history of stroke, are also associated with increased prevalence.[1]
- Cold, dry weather and season — symptoms characteristically worsen in winter and improve in summer.[3][1]
- Emotional stress and fatigue are recognized triggers for flares.[4][1]
- Family history of seborrheic dermatitis.
- Concurrent psoriasis or rosacea — an overlapping predisposition, and a source of diagnostic overlap (sebopsoriasis); see Diagnosis/Differential.
Red Flags & Refer
Complications
Left unaddressed, seborrheic dermatitis can be complicated by secondary bacterial or fungal infection of excoriated or fissured skin, by genuine treatment-induced harm (skin atrophy, telangiectasia, or a perioral-dermatitis-like eruption from prolonged, unsupervised topical corticosteroid use on the face), and — in richly pigmented skin — by postinflammatory hypo- or hyperpigmentation that can persist for weeks to months after the inflammation itself clears.[3][2] A more indirect but clinically important complication is diagnostic delay: missing seborrheic dermatitis as an early cutaneous marker of HIV infection, or failing to recognize its association with Parkinson's disease, both represent missed opportunities to identify or address a more consequential underlying condition.[4][5]
Most seborrheic dermatitis is straightforward to manage with the stepped topical approach in Choose Initial Treatment, but escalate assessment for any of the following:
- New, severe, widespread, or treatment-refractory seborrheic dermatitis in an adult with no clear explanation — particularly alongside other risk indicators (unexplained weight loss, oral thrush, recurrent infections) — warrants considering HIV testing; seborrheic dermatitis can be an early, presenting sign of HIV infection.[4]
- Signs of secondary bacterial infection — increasing pain rather than itch, spreading warmth or erythema, purulent drainage, or fever — need evaluation and treatment for infection in addition to, not instead of, ongoing seborrheic dermatitis management; see the Bacterial Skin Infections chapter.
- Signs suggesting a secondary or superimposed fungal infection (tinea) not responding to standard antifungal therapy — confirm with KOH microscopy rather than simply escalating the same treatment.[1]
- Diagnostic uncertainty, particularly a presentation that could instead be sebopsoriasis, psoriasis, or atopic dermatitis — reassess or refer to dermatology rather than continuing an ineffective treatment indefinitely.[1]
- No meaningful improvement after an adequate, adherent trial of appropriate first- and second-line therapy (see Treatment Failure/Next Step) — refer to dermatology.
- Extensive, thick, or treatment-resistant cradle cap in an infant, or cradle cap accompanied by failure to thrive, a rash spreading well beyond the scalp, or signs of infection — this pattern needs assessment beyond simple reassurance (see Special Populations).
- A new seborrheic-dermatitis-like eruption in a patient with newly diagnosed or poorly controlled Parkinson's disease, or seborrheic dermatitis worsening in step with a Parkinson's flare — coordinate with the treating neurology team rather than managing the skin and neurologic disease in isolation.[5]
Assessment & Diagnosis
Diagnosis is clinical
Seborrheic dermatitis is diagnosed by the location and appearance of the lesions — no laboratory test is routinely needed.[1] Ask specifically about symmetry, whether the distribution matches the classic sebum-rich sites, itch versus pain, and any known HIV status, neurologic diagnosis (particularly Parkinson's disease), or family history.
Differential diagnosis
| Condition | Features that point away from seborrheic dermatitis |
|---|---|
| Psoriasis (including sebopsoriasis) | Thicker, more sharply demarcated plaques with a silvery-white (rather than greasy yellow) scale, often also on extensor surfaces, with nail pitting or a family history of psoriasis; true sebopsoriasis is a recognized overlap syndrome combining features of both and can be genuinely difficult to distinguish clinically — biopsy occasionally helps.[1] |
| Atopic dermatitis | A symmetric, bilateral flexural distribution in adults (or facial/extensor involvement in the classic infant pattern), intense pruritus, and a personal or family history of atopy — a chronic, relapsing course without the specific sebum-rich-site distribution of seborrheic dermatitis.[1] |
| Contact dermatitis (irritant or allergic) | Distribution tied to an identifiable external contactant rather than to sebum-rich sites, and a genuinely different mechanism — a direct irritant effect or a Type IV hypersensitivity reaction to a specific external substance, not an inflammatory response to resident skin yeast; see the separate Contact Dermatitis chapter for full coverage of that condition. |
| Tinea capitis/corporis | Annular lesions with an active, scaling, elevated border and central clearing; confirm with KOH microscopy if uncertain, particularly before escalating topical corticosteroid potency.[1] |
| Pityriasis rosea | A herald patch followed by a "Christmas-tree" distribution of smaller oval lesions along skin cleavage lines on the trunk — a distinct, usually self-limited eruption unrelated to sebum-rich sites.[1] |
Investigations
Most patients need no testing beyond a careful history and examination. Reserve skin biopsy for genuine diagnostic uncertainty, particularly to distinguish seborrheic dermatitis from psoriasis or sebopsoriasis — supportive biopsy findings include parakeratosis, plugged follicular ostia, and spongiosis.[1] Perform KOH microscopy of scale when tinea is a realistic possibility, especially before adding or increasing topical corticosteroid potency, since an unrecognized fungal infection will predictably worsen under corticosteroid treatment. Consider HIV testing in an adult with new, severe, widespread, or treatment-refractory seborrheic dermatitis and no other clear explanation, particularly alongside other risk indicators — see Red Flags/Refer.[4]
Treatment Targets
- Control visible scale, erythema, and itch to an acceptable, cosmetically satisfactory level — this is a chronic, relapsing condition, and complete, permanent clearance from a single course is not a realistic goal.
- Match treatment potency and formulation to the affected site, with particular care on the face, where the skin is thin and corticosteroid side effects appear more readily.
- Correctly distinguish seborrheic dermatitis from psoriasis, atopic dermatitis, contact dermatitis, and tinea, since each has a genuinely different core treatment strategy.
- Establish a sustainable long-term maintenance strategy — typically an antifungal shampoo or cream continued once or twice weekly — rather than relying on repeated corticosteroid courses alone.
- Use a gentle, reassurance-focused approach in infants with cradle cap, reserving active treatment for extensive or persistent cases.
- Recognize when seborrheic dermatitis severity or distribution should prompt consideration of an underlying HIV infection or a neurologic condition such as Parkinson's disease, and act on that recognition.
- Avoid the specific, well-documented pitfalls of prolonged high-potency topical corticosteroid use on thin, sebum-rich facial skin.
Choose Initial Treatment
Step 1 — scalp disease (including dandruff)
1st line, OTC a keratolytic/antifungal medicated shampoo — ketoconazole 2%, selenium sulfide, zinc pyrithione, coal tar, or salicylic acid — applied 2-3 times weekly, left on the scalp for at least 5 minutes before rinsing so the active ingredient has time to work.[2][1] Once-weekly maintenance use after the scalp has cleared meaningfully reduces relapse.[2] 2nd line a prescription-strength antifungal shampoo (ketoconazole 2% or ciclopirox), used daily to every-other-day for the first 1-2 weeks, then 2-3 times weekly until clear.[1] Moderate-to-severe or itch-predominant scalp disease a corticosteroid solution, oil, or shampoo (for example fluocinolone acetonide 0.01%, or a short course of clobetasol propionate 0.05% for genuinely resistant disease) alternated with the antifungal shampoo — do not use a potent corticosteroid on the scalp as sole, indefinite maintenance therapy.[1][2]
Step 2 — face and body disease
1st line a topical antifungal (ketoconazole 2%, clotrimazole, miconazole, or terbinafine) applied once or twice daily — the preferred first-line agent for facial and body disease, with a more favourable long-term safety profile than continuous topical corticosteroid use.[1][2] Faster symptom relief, or an inadequate response to an antifungal alone a low-potency topical corticosteroid (hydrocortisone 1% or desonide 0.05%) for a short course only — reserve higher potencies for short, supervised bursts, given how readily facial skin absorbs topical corticosteroid.[1] Steroid-sparing option, particularly for the face, eyelids, and long-term/maintenance use a topical calcineurin inhibitor (pimecrolimus or tacrolimus) or the newer topical PDE4 inhibitor roflumilast — each is a reasonable option without the atrophy/telangiectasia risk of a corticosteroid, making it a genuinely reasonable default for chronic facial disease rather than only a fallback.[1][2]
Step 3 — severe, extensive, or treatment-resistant disease
Refractory to an adequate topical regimen an oral antifungal — terbinafine 250 mg once daily for 4-6 weeks, or itraconazole 200 mg once daily for 7 days followed by monthly pulse dosing — under dermatology guidance.[2] Severe, truncal, or genuinely refractory disease low-dose oral isotretinoin (up to about 0.5 mg/kg/day) is a described, though off-label, option in reported case series, with truncal disease responding particularly well — this needs dermatology initiation given the monitoring and pregnancy-prevention requirements described in the Acne chapter.[2]
Cradle cap (infants)
1st line, nearly all infants gentle, non-pharmacologic care only — see Non-Pharmacologic Management — since cradle cap is typically self-limited and resolves within the first several months to about a year of life without any medication.[3][6] Extensive, thick, or persistent despite gentle care ketoconazole 2% cream applied once or twice daily for about 2 weeks, or a brief course of a low-potency topical corticosteroid (hydrocortisone 1%) — reserve for genuinely extensive or persistent cases rather than routine use.[1]
Non-Pharmacologic Treatment
- Regular, gentle shampooing — 2-3 times weekly for straight or wavy hair, up to daily for a very oily scalp, and less often (roughly weekly) for coily/textured hair, adjusting to the patient's actual hair type and washing tolerance.[3][1]
- Use a mild, fragrance-free cleanser on the face and body rather than harsh soap, which can itself irritate already-inflamed skin.
- Do not vigorously scrub or pick at scale — this worsens inflammation and irritation without speeding clearance.
- For infant cradle cap: soften scales first with a bland emollient (mineral oil or plain petroleum jelly) left on for several minutes to about an hour, then gently loosen and remove loose scale with a soft brush or washcloth before a mild baby shampoo — never use an adult dandruff or tar shampoo on an infant's scalp.[1][6]
- Reassure caregivers that cradle cap is benign, is not caused by poor hygiene, is not contagious, and typically resolves on its own within the first year of life.[3][6]
- Counsel that seborrheic dermatitis at any age is not caused by poor hygiene and is not contagious — a common and unhelpful misconception worth actively correcting.[6]
- Manage cold-weather and stress-related flares proactively wherever a clear seasonal or stress pattern is identified, since both are recognized triggers.[3][4]
Special Populations
Infants (cradle cap)
Cradle cap is infantile seborrheic dermatitis of the scalp, typically appearing between 2 and 12 months of age as thick, greasy, white-to-yellow scale, sometimes with mild underlying erythema, and occasionally extending to the eyebrows, ears, or diaper area.[1][6] It is a benign, self-limited condition that resolves spontaneously, usually within the first several months to about a year of life, and needs no medication in the great majority of cases — gentle emollient softening plus brushing and a mild shampoo is both first-line and usually sufficient (see Non-Pharmacologic Management).[3][6][1] Reserve topical ketoconazole or a brief low-potency corticosteroid course for extensive, thick, or persistent disease, and remember that no medicated dandruff shampoo is approved for children under 2 years — do not substitute an adult antifungal or tar shampoo.[1]
Pregnancy
Topical antifungals (ketoconazole, clotrimazole, miconazole) and low-potency topical corticosteroids are generally considered compatible in pregnancy given minimal systemic absorption at recommended topical use, and are reasonable first-line choices. Oral antifungal therapy and oral isotretinoin are both reserved for severe, refractory disease even in the general population and are not appropriate choices in pregnancy — isotretinoin is a confirmed teratogen and is absolutely contraindicated; discuss any oral therapy need with the prescriber.
Breastfeeding
Topical antifungals and low-to-moderate potency topical corticosteroids are compatible with breastfeeding; wash the treated area before the next feed if applied near the breast or nipple. Topical calcineurin inhibitors are also generally considered compatible given minimal systemic absorption.
Older adults
Skin thins with age, increasing both topical corticosteroid absorption and the visible impact of atrophy and purpura — favour topical antifungals and topical calcineurin inhibitors as first-line, and use the lowest effective corticosteroid potency for the shortest effective course. Seborrheic dermatitis is also more prevalent in patients with neurologic disease more common in this age group, including Parkinson's disease and a history of stroke — a new or worsening presentation may be worth flagging to the treating physician rather than assumed to be purely dermatologic.[1]
Darker skin tones
Petaloid (annular, ring-shaped) presentation is more common, and postinflammatory hypo- or hyperpigmentation is a genuinely expected part of the disease course that can persist for weeks to months after the inflammation itself has cleared — counsel on this explicitly so it is not mistaken for treatment failure or a different diagnosis.[3][2]
HIV infection and other immunosuppression
Seborrheic dermatitis is markedly more prevalent (roughly 30-83%) and tends to be more severe, more widespread, and more difficult to treat in HIV-positive patients than in the general population, and it commonly appears early in the course of HIV disease — sometimes as one of the first clinical signs.[4] A butterfly-distribution facial rash that does not respond to standard treatment can even be mistaken for discoid lupus erythematosus unless the underlying immunosuppression is recognized, and tinea faciei can mimic seborrheic dermatitis in this population — a KOH examination is worthwhile whenever the diagnosis is in doubt.[4] Expect a more prolonged, higher-intensity treatment course, and consider HIV testing in a patient with no established diagnosis and no other explanation for severe or refractory disease (see Diagnosis/Differential and Red Flags/Refer).
Parkinson's disease
Seborrheic dermatitis occurs in roughly two-thirds of patients with Parkinson's disease — substantially more than in controls — and severity tracks Parkinson's disease severity and phenotype, with the akinetic-rigid subtype showing greater seborrheic dermatitis severity than the tremor-predominant subtype in a recent cross-sectional study.[5] Despite this strong association, regular dermatologic follow-up in this population is often inconsistent, so proactively screening for and addressing seborrheic dermatitis at routine visits is worthwhile rather than waiting for the patient to raise it.[5]
Monitoring & Follow-Up
Reassess within 2-4 weeks of starting a new topical regimen to confirm both improvement and genuine adherence. Set realistic expectations from the outset: seborrheic dermatitis is a chronic, relapsing condition, not one cured with a single course of treatment, and most patients will need an ongoing maintenance strategy — typically an antifungal shampoo or cream continued once or twice weekly — to keep it controlled long-term; once-weekly maintenance antifungal shampoo use has been shown to meaningfully reduce relapse.[2] Continued or fluctuating disease despite adherence does not necessarily mean the medication has failed outright — the disease's natural, variable course means some fluctuation in control is expected — but it should still prompt reassessment rather than blind escalation.[1]
Patient education
Every patient (or caregiver, for cradle cap) should leave the visit understanding: seborrheic dermatitis is not caused by poor hygiene and is not contagious;[6] it is a chronic, relapsing condition best managed with an ongoing, typically low-effort maintenance routine rather than a one-time cure; facial skin needs gentler, more time-limited corticosteroid use than the scalp or body; and postinflammatory pigment change in darker skin is an expected, gradually-fading part of the healing process, not a treatment failure.
Common Errors to Avoid
- Using a moderate- or high-potency topical corticosteroid continuously on the face for maintenance therapy — a leading cause of preventable atrophy, telangiectasia, and perioral-dermatitis-like eruptions in this condition; step down to an antifungal or a calcineurin inhibitor once controlled.
- Treating seborrheic dermatitis as if it were contact dermatitis, or vice versa — the two have genuinely different mechanisms and treatment strategies; see Recognize the Condition and the separate Contact Dermatitis chapter.
- Using an adult-strength medicated dandruff or tar shampoo on an infant's scalp — cradle cap needs a much gentler approach, and no medicated shampoo is approved for children under 2 years.
- Missing sebopsoriasis or underlying psoriasis in a patient not responding to standard seborrheic dermatitis therapy.
- Overlooking the opportunity to consider HIV testing in an adult with new, severe, or refractory disease and no other explanation.
- Assuming cradle cap needs aggressive scale removal — vigorous picking or scrubbing worsens irritation without speeding resolution.
- Reaching for an oral antifungal or isotretinoin course as an early option rather than reserving it for genuinely severe or topical-therapy-refractory disease.
- Not establishing a maintenance plan once disease is controlled, leading to an entirely avoidable cycle of repeated acute flares and repeated corticosteroid courses.
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
Scalp — First-Line OTC Shampoos
Applied 2-3 times weekly, left on the scalp at least 5 minutes before rinsing; reduce to once-weekly maintenance once clear.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Ketoconazole 2%, shampoo | Dosing: Apply 2-3x weekly, leave on 5+ minutes; once weekly for maintenance | Local burning/stinging (uncommon) | None clinically significant with topical use | A meta-analysis found a 31% lower risk of failing to clear by week 4 versus placebo; once-weekly maintenance meaningfully reduces relapse. |
| Selenium sulfide 2.5%, shampoo | Dosing: Apply 2x weekly | Scalp irritation, oiliness/dryness of hair, discoloration of light-coloured hair with overuse | None significant | No Pharmasist Drug Database monograph currently exists for this OTC product; named as text only. |
| Zinc pyrithione, shampoo | Dosing: Apply 2-3x weekly, or daily-use formulations per product labelling | Local irritation (uncommon) | None significant | No Pharmasist Drug Database monograph currently exists for this OTC product; named as text only. |
| Coal tar, shampoo | Dosing: Apply to wet scalp/hair, leave on as directed, then rinse, 2-3x weekly | Skin irritation, folliculitis, photosensitivity; malodour and staining of skin/hair/fabric | Additive photosensitivity with other photosensitizing medications | Inexpensive, effective, long-standing option; adherence is often limited by odour and staining. |
| Salicylic acid, shampoo | Dosing: Apply 1-2x weekly | Local irritation, scaling; salicylate toxicity with prolonged large-area use, especially in children | Theoretical additive salicylate exposure with high-dose oral salicylate use | Keratolytic adjunct that improves penetration of a co-applied antifungal or corticosteroid; not a stand-alone anti-inflammatory. |
Scalp — Prescription-Strength / 2nd Line
Reserve for scalp disease inadequately controlled by an OTC shampoo, or for moderate-to-severe/itch-predominant disease.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Ciclopirox 1%, shampoo | Dosing: Apply 2x weekly for 4 weeks, at least 3 days apart | Local irritation | None significant | Trial data show roughly half of patients with little or no seborrheic dermatitis remaining after 4 weeks. |
| Fluocinolone acetonide 0.01%, topical oil/solution | Dosing: Apply once or twice daily for up to about 2 weeks | Local irritation; atrophy with prolonged/continuous use | None significant at recommended topical doses | Oil vehicle contains peanut oil (not peanut protein) — confirm patient/caregiver comfort before use. Alternate with an antifungal shampoo; not a maintenance agent. |
| Clobetasol propionate 0.05%, scalp application | Dosing: Apply once or twice daily; brief courses only, maximum about 50 g/week | Skin atrophy, striae, HPA-axis suppression with prolonged/extensive use | None clinically significant with topical use at recommended doses | Reserve for genuinely resistant scalp disease; never a maintenance agent — step down to an antifungal shampoo once controlled. |
Face and Body — Topical Antifungals (1st Line)
Preferred first-line agents for facial and body disease, with a more favourable long-term safety profile than continuous topical corticosteroid use.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Ketoconazole 2%, cream | Dosing: Apply BID for up to 8 weeks, then PRN | Local burning/stinging (uncommon) | None clinically significant with topical use | 1st-line topical antifungal for face/body disease. |
| Clotrimazole 1%, cream | Dosing: Apply BID | Local irritation | None significant | Reasonable substitute if ketoconazole is not tolerated or available. |
| Miconazole 2%, cream | Dosing: Apply BID | Local irritation | None significant | Another reasonable topical antifungal alternative for face/body disease. |
| Terbinafine 1%, cream | Dosing: Apply once or twice daily | Local irritation | None significant | A further topical antifungal option distinct from oral terbinafine (see Severe/Resistant Disease below). |
Face and Body — Topical Corticosteroids (2nd Line, Short Courses Only)
Reserve for faster symptom relief or an inadequate response to a topical antifungal alone; use the lowest effective potency for the shortest effective course, especially on the face.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Hydrocortisone 1%, topical | Dosing: Apply once or twice daily, short courses | Local irritation; atrophy uncommon at this potency | None clinically significant given minimal systemic absorption | Preferred low-potency choice for the face and skin folds. In a head-to-head trial it actually cleared more patients (94.4%) than ketoconazole 2% cream (80.5%) — but prolonged use still risks atrophy/tachyphylaxis, so reserve for short courses. |
| Desonide 0.05%, topical | Dosing: Apply once or twice daily, short courses | Local irritation; atrophy and striae uncommon at this potency | None clinically significant given minimal systemic absorption | A reasonable low-mid potency alternative to hydrocortisone for sensitive sites. |
| Betamethasone (mid-high potency), topical | Dosing: Apply BID, short courses | Striae, telangiectasia, atrophy with prolonged use | None clinically significant at recommended topical doses | Not for the face or skin folds — reserve for thicker or resistant trunk/body lesions inadequately controlled by a low-potency agent. |
Steroid-Sparing / Long-Term Maintenance
No corticosteroid-type atrophy risk — genuinely reasonable defaults for chronic facial disease and long-term maintenance, not only fallback options.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Pimecrolimus 1%, cream | Dosing: Apply BID | Transient application-site burning, most prominent in the first few days | None significant at topical doses | Preferred topical calcineurin inhibitor for face/folds and long-term maintenance. |
| Tacrolimus 0.1%, topical ointment | Dosing: Apply BID | Transient application-site burning | None significant at topical doses | Alternative topical calcineurin inhibitor with the same steroid-sparing rationale as pimecrolimus. |
| Roflumilast 0.3%, foam | Dosing: Apply once daily | Application-site burning/stinging (uncommon); diarrhea, headache (uncommon) | None significant at topical doses | Newer topical PDE4 inhibitor; in phase 3 trials, 79.5% achieved clear/almost-clear skin with at least a 2-point improvement by week 8, versus 58% with vehicle foam. |
Infant Cradle Cap
Gentle, non-pharmacologic care is first-line and usually sufficient; reserve medication for extensive or persistent disease.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Mineral oil, emollient | Dosing: Apply to the scalp, leave 15-60 minutes (or overnight), then gently remove loosened scale before a mild shampoo | Local greasiness only | None significant | Softens adherent scale before gentle brushing/combing; avoid vigorous scraping. |
| Baby shampoo, mild | Dosing: Use routinely in place of adult shampoo | None significant | None significant | Used in place of an adult dandruff or tar shampoo, which is not appropriate for an infant's scalp; no Pharmasist Drug Database monograph exists for this product category. |
| Ketoconazole 2%, cream | Dosing: Apply once or twice daily for about 2 weeks | Local irritation (uncommon) | None clinically significant with topical use | Reserve for extensive, thick, or persistent cradle cap despite gentle care. |
| Hydrocortisone 1%, topical | Dosing: Apply once or twice daily, brief course | Local irritation; atrophy uncommon at this potency | None clinically significant given minimal systemic absorption | Reserve for genuinely extensive or persistent cradle cap; a brief course only. |
Severe/Resistant Disease — Systemic Therapy
Reserve for disease refractory to an adequate topical regimen; dermatology-initiated given the monitoring burden of these agents.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Terbinafine, oral | Adults: 250 mg PO once daily for 4-6 weeks | GI upset, headache, transient taste/smell disturbance; rare hepatotoxicity | Numerous CYP2D6-mediated interactions — review the full medication list | Obtain baseline liver function tests before starting. |
| Itraconazole, oral (pulse) | Adults: 200 mg PO once daily for 7 days, repeated monthly | GI upset, headache; rare hepatotoxicity, heart failure | Potent CYP3A4 inhibitor with an extensive interaction list — screen the full medication list before dispensing | Pulse dosing is preferred over continuous dosing for a lower cumulative interaction/side-effect burden. |
| Isotretinoin, oral (low dose) | Adults: Up to about 0.5 mg/kg/day | Mucocutaneous dryness, teratogenicity, hyperlipidemia, hepatotoxicity | Avoid concurrent tetracyclines (pseudotumor cerebri risk); numerous others — review the full profile | Off-label for this indication; truncal disease responds particularly well in reported series. Requires the same monitoring and pregnancy-prevention program described in the Acne chapter. |
References
- Diagnosis and Treatment of Seborrheic Dermatitis — American Family Physician (Clark GW, Pope SM, Jaboori KA). Am Fam Physician 2015;91(3):185-190
- Current Understanding of Seborrheic Dermatitis: Treatment Options — Journal of Cutaneous Medicine and Surgery (Turchin I, Albrecht L, Hanna S, Kyritsis D, Loo WJ, Lynde CW, Prajapati VH, Purdy K, Rochette L, Wiseman M, Wong D, Yadav G, Yeung J, Gooderham M). J Cutan Med Surg 2025;29(4_suppl):24S-36S
- Dandruff — Canadian Dermatology Association. dermatology.ca, Patient Information
- Seborrheic Dermatitis – An Early and Common Skin Manifestation in HIV Patients — Acta Dermatovenerologica Croatica (Chatzikokkinou P, Sotiropoulos K, Katoulis A, Luzzati R, Trevisan G). Acta Dermatovenerol Croat 2008;16(4):226-230
- The Association of Seborrheic Dermatitis and Parkinson's Disease: A Cross-Sectional Study — Journal of the American Academy of Dermatology (Wilkowski CM, Alhajj M, Kilbane CW, Kumar Y, Bordeaux JS, Carroll BT). J Am Acad Dermatol 2025;92(1):157-159
- What Is Seborrheic Dermatitis? — Eczema Society of Canada. eczemahelp.ca, Patient Information
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.